LAAA

SC 13G/A - Lakeshore Acquisition I Corp. (0001848000) (Subject)

Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol "OSA" SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) --  ProSomnus, Inc. ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. ("Lakeshore") (NASDAQ:LAAA), a publicly traded special purpose acquisition company. ProSomnus will commence trading on the Nasdaq Global Market under the symbol "OSA" on Dec. 7, 2022. The business combination, which was approved by Lakeshore's shareholders

25-NSE - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K/A - Lakeshore Acquisition I Corp. (0001848000) (Filer)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

Lakeshore Acquisition I Corp. (NASDAQ:LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus") at a special meeting of shareholders held on December 2, 2022. Approximately 92.4% of the votes cast at the meeting on the Business Combination proposal, representing approximately 80.5% of Lakeshore's outstanding shares, voted to approve the Business Combination. The closing of the Business Combination is anticipated to occur on or about December 6, 2022.  Following the closing, the combined company will operate as ProSomnus, Inc., and its

SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (NASDAQ:LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus") at a special meeting of shareholders held on December 2, 2022. Approximately 92.4% of the votes cast at the meeting on the Business Combination proposal, representing approximately 80.5% of Lakeshore's outstanding shares, voted to approve the Business Combination. The closing of the Business Combination is anticipated to occur on or about December 6, 2022.  Following the closing, the combined compan

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022 Company Updates 2022 Revenue Guidance to range of $19.0 - $19.5 million for full year 2022 SAN FRANCISCO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ProSomnus ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea ("OSA"), today announced results for the third quarter ended September 30, 2022 and provided a business update. Recent Highlights Record revenues for the first nine months of 2022 of $13.6 million, a 40.6% year-over-year. Revenues in the third quarter were $5.0 million, also a record.Gross margins for the first

DEFM14A - Lakeshore Acquisition I Corp. (0001848000) (Filer)

10-Q - Lakeshore Acquisition I Corp. (0001848000) (Filer)

Device expands ProSomnus' suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered to provide Medicare beneficiaries and their healthcare providers with new options for treating OSA SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- ProSomnus ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the ProSomnus EVO™ [PH] Sleep and Snore Device. The device joins the Company's flagship product, the ProSomnus EVO™, in its line of FDA-cleared, patie

Soon to be listed, ProSomnus has received FDA 510(k) clearance for its flagship product, ProSomnus EVO [PH] Sleep and Snore Device.  ProSomnus EVO is a less invasive Precision Oral Appliance Therapy (OAT) device for Obstructive Sleep Apnea (OSA). What Happened: ProSomnus EVO [PH] device uses mechanical hinge components to reposition and stabilize the patient's jaw during sleep, increasing pharyngeal space and reducing the risk of upper airway collapse.  The device is approximately 13% smaller than predicate devices and features comfort bumps around key components.  The device features advancement markings and visual indicators to make it easier for beneficiaries to communicate with their

SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ProSomnus Holdings Inc. ("ProSomnus"), the leader in patient preferred medical devices for the treatment of obstructive sleep apnea (OSA), today announced that Laing Rikkers, Executive Chairwoman and Co-Founder, is scheduled to participate at the Oppenheimer Private Company Showcase on October 17-18, 2022 at the Four Seasons in Palo Alto, California. Laing Rikkers will present at 10:25 am Pacific Time, and will be available for investor meetings throughout both days. About ProSomnusProSomnus is the first manufacturer of precision, mass-customized oral appliance therapy devices to treat OSA, which affects over 74 million Americans and is ass

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the ProSomnus EVOTM Sleep and Snore Device is now reimbursable by Germany's public health insurance system. The ProSomnus EVO is an alternative to legacy oral devices and CPAP machines, and can result in more effective treatment and superior patient compliance. It repositions and stabilizes the jaw during sleep, improving airflow through a patient's pharyngeal space. The ProSomnus EVO consists of maxillary and mandibular aligner trays for orthodontic treatment that are precision-manufactured with twin-mated posts, and

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)